Clinical outcome following post‐chemotherapy retroperitoneal lymph node dissection in men with intermediate‐ and poor‐risk nonseminomatous germ cell tumour
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
As usual, the urological oncology section is quite full, and covers a range of topics. Authors from New York describe their considerable experience with retroperitoneal lymph node dissection after chemotherapy, and make some important recommendations about the procedure in men initially diagnosed with intermediate‐ and poor‐risk nonseminomatous germ cell tumours. There are several papers on prostate cancer, and on renal and bladder cancer. As can be seen, the role of chemotherapy in prostate cancer is receiving increasing attention.OBJECTIVETo evaluate the outcome in patients treated with chemotherapy and retroperitoneal lymph node dissection (RPLND) after an initial diagnosis of International Germ Cell Cancer Collaborative Group (IGCCCG) intermediate‐ and poor‐risk metastatic nonseminomatous testicular germ cell tumour (NSGCT), as the integration of chemotherapy and surgery in managing advanced NSGCT continues to develop.PATIENTS AND METHODSBetween 1989 and 2003, 157 patients initially diagnosed with IGCCCG intermediate‐ and poor‐risk NSGCT had RPLND after chemotherapy at the authors’ institution, with a median follow‐up of 36 months. Progression‐free probability (PFP) and disease‐specific survival (DSS) were estimated using the Kaplan–Meier method. Cox proportional hazards regression analysis was used to assess the prognostic significance of risk factors for disease progression after RPLND.RESULTSIn all, 68 (43%) and 89 (57%) patients were assigned as intermediate‐ and poor‐risk, respectively. At the time of RPLND the median residual retroperitoneal mass was 3.0 cm and 29 (19%) men had elevated serum tumour markers (α‐fetoprotein, human chorionic gonadotrophin, or both). Retroperitoneal residual masses were completely resected in 147 (94%) patients; retroperitoneal histology revealed fibrosis in 73 (47%), teratoma in 63 (40%) and viable GCT in 21 (13%). The 5‐year overall DSS and PFP were 81% and 70%, respectively. Patients with poor‐risk NSGCT were at no greater risk of disease progression than those with intermediate‐risk NSGCT. In a multivariate analysis, residual mass size, incomplete surgical resection and the presence of teratoma and viable germ cell cancer independently predicted disease progression after RPLND.CONCLUSIONSPatients with advanced NSGCT have long‐term freedom from disease progression when chemotherapy is combined with resection of residual masses. Our data suggest that the tumour response to chemotherapy, coupled with complete resection of all residual masses, predicts long‐term freedom from disease progression.
